{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:54:55Z","timestamp":1789732495218,"version":"4.0.1"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.athplu.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T05:29:47Z","timestamp":1708147787000},"page":"74-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023"],"prefix":"10.1016","volume":"55","author":[{"given":"N","family":"Katsiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Td","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Panagiotakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Garoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rallidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nomikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kypreos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Chrysohoou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tziomalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Skoumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Koutagiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Attilakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Papagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Boutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pitsavos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Liberopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2024.01.004_bib1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"European Heart Journal 2021"},{"key":"10.1016\/j.athplu.2024.01.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hjc.2022.10.002","article-title":"Twenty-first century epidemiology of dyslipidemia in Greece: EMENO national epidemiological study","volume":"69","author":"Stergiou","year":"2023","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.5114\/aoms.2018.73961","article-title":"Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II","volume":"15","author":"Liberopoulos","year":"2019","journal-title":"Aoms"},{"key":"10.1016\/j.athplu.2024.01.004_bib4","first-page":"111","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J 2020"},{"key":"10.1016\/j.athplu.2024.01.004_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.hjc.2020.03.006","article-title":"The recalibrated HellenicSCORE based on newly derived risk factors from the hellenic national nutrition and health Survey (HNNHS); the HellenicSCORE II","volume":"62","author":"Panagiotakos","year":"2021","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib6","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology\/American heart association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation 2019"},{"key":"10.1016\/j.athplu.2024.01.004_bib7","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.athplu.2024.01.004_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM200007063430103","article-title":"Primary prevention of coronary heart disease in women through diet and lifestyle","volume":"343","author":"Stampfer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.106.621417","article-title":"Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications","volume":"114","author":"Chiuve","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2024.01.004_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib11","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib13","author":"Leqvio- inclisiran"},{"key":"10.1016\/j.athplu.2024.01.004_bib14","series-title":"FDA approves add-on therapy to lower cholesterol among certain high-risk adults","year":"2021"},{"key":"10.1016\/j.athplu.2024.01.004_bib15","article-title":"Inclisiran: a first-in-class siRNA therapy for lowering low-density lipoprotein cholesterol","author":"Samuel","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.athplu.2024.01.004_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-022-01056-0","article-title":"Inclisiran: how widely and when should we use it?","author":"Pirillo","year":"2022","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MED.0000000000000706","article-title":"New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia","volume":"29","author":"Pirillo","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.athplu.2024.01.004_bib18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/dtb.2022.000035","article-title":"Bempedoic acid: another cholesterol-lowering drug","volume":"60","year":"2022","journal-title":"Drug Therapeut Bull"},{"key":"10.1016\/j.athplu.2024.01.004_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11883-020-00860-w","article-title":"Selective peroxisome proliferator-activated receptor alpha modulators (SPPARM\u03b1): new opportunities to reduce residual cardiovascular risk in chronic kidney disease?","volume":"22","author":"Fruchart","year":"2020","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib22","series-title":"EMA confirms omega-3 fatty acid medicines are not effective in preventing further heart problems after a attack","year":"2019"},{"key":"10.1016\/j.athplu.2024.01.004_bib23","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2024.01.004_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib25","unstructured":"FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups. Accessed on 15\/September\/2022 [n.d]."},{"key":"10.1016\/j.athplu.2024.01.004_bib26","unstructured":"Vazkepa. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vazkepa. Accessed on 15-September-2022 [n.d]."},{"key":"10.1016\/j.athplu.2024.01.004_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00041433-199906000-00005","article-title":"Lipoprotein(a): intrigues and insights","volume":"10","author":"Hobbs","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib29","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2024.01.004_bib30","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2024.01.004_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of lLPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib32","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","article-title":"Current role of lipoprotein apheresis","volume":"21","author":"Thompson","year":"2019","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib34","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2024.01.004_bib35","unstructured":"Lp(a)HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events.https:\/\/www.prnewswire.com\/news-releases\/lpa-horizon-achieves-50-enrollment-in-trial-to-assess-the-safety-and-efficacy-of-pelacarsen-in-reducing-recurrent-cardiovascular-events-301346042.html. Accessed on 12-October-2022 n.d. ."},{"key":"10.1016\/j.athplu.2024.01.004_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the olpasiran trials of cardiovascular events and lipoprotein(a) reduction-dose finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.athplu.2024.01.004_bib37","unstructured":"AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a). https:\/\/www.amgen.com\/newsroom\/press-releases\/2022\/05\/amgen-announces-positive-topline-phase-2-data-for-investigational-olpasiran-in-adults-with-elevated-lipoproteina. Accessed on 12-October-2022 n.d. ."},{"key":"10.1016\/j.athplu.2024.01.004_bib38","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2024.01.004_bib39","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib40","first-page":"1289","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J 2021"},{"key":"10.1016\/j.athplu.2024.01.004_bib41","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","volume":"54","author":"Cleland","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib42","first-page":"3599","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J 2021"},{"key":"10.1016\/j.athplu.2024.01.004_bib43","series-title":"EVOlocumab in stable heart failure with reduced ejection fraction of ischemic Etiology: EVO-HF Pilot","year":"2021"},{"key":"10.1016\/j.athplu.2024.01.004_bib44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2024.01.004_bib45","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2024.01.004_bib46","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1212\/WNL.0000000000007935","article-title":"Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke","volume":"93","author":"Boulanger","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.athplu.2024.01.004_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.athplu.2024.01.004_bib48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib49","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2024.01.004_bib50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib51","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/01.wnl.0000269789.09277.47","article-title":"Statin treatment withdrawal in ischemic stroke: a controlled randomized study","volume":"69","author":"Blanco","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.athplu.2024.01.004_bib52","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1161\/STROKEAHA.117.017623","article-title":"Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT trial (administration of statin on acute ischemic stroke patient)","volume":"48","author":"Yoshimura","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.athplu.2024.01.004_bib53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5853\/jos.2015.17.3.282","article-title":"Statins in acute ischemic stroke: a systematic review","volume":"17","author":"Hong","year":"2015","journal-title":"J Stroke"},{"key":"10.1016\/j.athplu.2024.01.004_bib54","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2024.01.004_bib55","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.athplu.2024.01.004_bib56","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","article-title":"Effect of alirocumab on stroke in ODYSSEY OUTCOMES","volume":"140","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2024.01.004_bib57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","article-title":"KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD","volume":"65","author":"Sarnak","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.athplu.2024.01.004_bib58","article-title":"Mild-to-moderate kidney dysfunction and cardiovascular disease: observational and mendelian randomization analyses","volume":"122","author":"Gaziano","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2024.01.004_bib59","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-019-45431-5","article-title":"Cholesterol-lowering treatment in chronic kidney disease: multistage pairwise and network meta-analyses","volume":"9","author":"Herrera-G\u00f3mez","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib60","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2024.01.004_bib61","article-title":"Effects of statins on cardiovascular outcomes in patients with chronic kidney disease","volume":"9","author":"Kosmas","year":"2017","journal-title":"Clin Med Insights Ther"},{"key":"10.1016\/j.athplu.2024.01.004_bib62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib63","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib64","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.athplu.2024.01.004_bib65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2016.01.005","article-title":"The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: a meta-analysis","volume":"105","author":"Zhang","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.athplu.2024.01.004_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/0003319714550309","article-title":"Contrast-induced nephropathy: an \u201call or none\u201d phenomenon?","volume":"66","author":"Katsiki","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.athplu.2024.01.004_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0003319718801246","article-title":"Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: a network meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.athplu.2024.01.004_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40256-016-0164-5","article-title":"Efficacy of short-term statin treatment for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography\/percutaneous coronary intervention: a meta-analysis of 21 randomized controlled trials","volume":"16","author":"Li","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.athplu.2024.01.004_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019473","article-title":"Beneficial effect of statin on preventing contrast-induced acute kidney injury in patients with renal insufficiency: a meta-analysis","volume":"99","author":"Cho","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.athplu.2024.01.004_bib70","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/14656566.2019.1649394","article-title":"Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease","volume":"20","author":"Katsiki","year":"2019","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.athplu.2024.01.004_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/jrms.JRMS_772_19","article-title":"Fenofibrate-induced renal dysfunction, yes or no?","volume":"25","author":"Emami","year":"2020","journal-title":"J Res Med Sci"},{"issue":"I\u2013IV","key":"10.1016\/j.athplu.2024.01.004_bib72","first-page":"S1","article-title":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group. K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.athplu.2024.01.004_bib73","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/CIRCULATIONAHA.121.058983","article-title":"Statin use in pregnancy: is it time for a paradigm shift?","volume":"145","author":"Mauricio","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2024.01.004_bib74","unstructured":"Statins: Drug Safety Communication - FDA Requests Removal of Strongest Warning Against Using Cholesterol-lowering Statins During Pregnancy. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/statins-drug-safety-communication-fda-requests-removal-strongest-warning-against-using-cholesterol. Accessed on 12-October-2022 n.d. ."},{"key":"10.1016\/j.athplu.2024.01.004_bib75","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/HCO.0000000000000407","article-title":"Dyslipidaemia in type 2 diabetes mellitus: bad for the heart","volume":"32","author":"Katsiki","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib76","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/1570161115666170201105425","article-title":"Pathophysiology of diabetic dyslipidaemia","volume":"15","author":"Filippatos","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.athplu.2024.01.004_bib77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2024.01.004_bib78","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.2174\/1381612811319270014","article-title":"Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance","volume":"19","author":"Banach","year":"2013","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.athplu.2024.01.004_bib79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1074248418757011","article-title":"Hypolipidemic drugs and diabetes mellitus\u2014mechanisms and data from genetic trials","volume":"23","author":"Filippatos","year":"2018","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.athplu.2024.01.004_bib80","first-page":"471","article-title":"New-onset diabetes and statins: throw the bath water out","volume":"64","author":"Katsiki","year":"2015","journal-title":"but, please, keep the baby! Metabolism"},{"key":"10.1016\/j.athplu.2024.01.004_bib81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes\u2014it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.athplu.2024.01.004_bib82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2047487315579291","article-title":"An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study","volume":"23","author":"Friis-M\u00f8ller","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib83","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/14656566.2016.1187133","article-title":"Drug therapies for HIV-related metabolic disorders","volume":"17","author":"Lamarca","year":"2016","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.athplu.2024.01.004_bib84","series-title":"Lipid disorders in people with HIV","author":"Sarkar","year":"2000"},{"key":"10.1016\/j.athplu.2024.01.004_bib85","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study","volume":"75","author":"Boccara","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib86","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib87","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.acvd.2010.03.007","article-title":"High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis","volume":"103","author":"Meune","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.athplu.2024.01.004_bib88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autrev.2015.10.002","article-title":"Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis","volume":"15","author":"Wu","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.athplu.2024.01.004_bib89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthitis Care Res"},{"key":"10.1016\/j.athplu.2024.01.004_bib90","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005892","article-title":"Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies","volume":"6","author":"Feng","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2024.01.004_bib91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2005.12.006","article-title":"Inflammation: a pivotal link between autoimmune diseases and atherosclerosis","volume":"5","author":"Abou-Raya","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.athplu.2024.01.004_bib92","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3899\/jrheum.090011","article-title":"Risk factors for development of coronary artery disease in women with systemic lupus erythematosus","volume":"36","author":"Goldberg","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.athplu.2024.01.004_bib93","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/eurheartj\/ehv461","article-title":"Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome","volume":"36","author":"Mantel","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2024.01.004_bib94","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570161115666170621075619","article-title":"Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?","volume":"16","author":"Katsiki","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.athplu.2024.01.004_bib95","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.athplu.2024.01.004_bib96","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib97","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.athplu.2024.01.004_bib98","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.arteri.2021.10.001","article-title":"Dietary patterns in non-alcoholic fatty liver disease (NAFLD): stay on the straight and narrow path","volume":"34","author":"Katsiki","year":"2022","journal-title":"Cl\u00edn Invest Arterioscler"},{"key":"10.1016\/j.athplu.2024.01.004_bib99","first-page":"17","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk","volume":"71","author":"Athyros","year":"2017","journal-title":"An Expert Panel Statement. Metabolism"},{"key":"10.1016\/j.athplu.2024.01.004_bib100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib101","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2024.01.004_bib102","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.athplu.2024.01.004_bib103","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.athplu.2024.01.004_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/9394381","article-title":"A meta-analysis of statin use and risk of hepatocellular carcinoma","volume":"2022","author":"Wang","year":"2022","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.athplu.2024.01.004_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.athplu.2024.01.004_bib106","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib107","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF03401398","article-title":"Expert consensus on the rational clinical use of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors","volume":"15","author":"Achimastos","year":"2016","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.athplu.2024.01.004_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.athplu.2024.01.004_bib109","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","article-title":"Statin-associated muscle disease: advances in diagnosis and management","volume":"15","author":"Taylor","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.athplu.2024.01.004_bib110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin-associated myopathy","volume":"159","author":"Rallidis","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib112","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2024.01.004_bib113","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2024.01.004_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.3009","article-title":"Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)","volume":"41","author":"Wright","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2024.01.004_bib115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","volume":"16","author":"Laufs","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.athplu.2024.01.004_bib117","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4140\/TCP.n.2019.253","article-title":"Vitamin D supplementation to treat statin-associated muscle symptoms: a review","volume":"34","author":"Lowe","year":"2019","journal-title":"Sr Care Pharm"},{"key":"10.1016\/j.athplu.2024.01.004_bib118","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/nutrit\/nux047","article-title":"Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel","volume":"75","author":"Cicero","year":"2017","journal-title":"Nutr Rev"},{"key":"10.1016\/j.athplu.2024.01.004_bib119","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The role of nutraceuticals in statin intolerant patients","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HCO.0000000000000874","article-title":"Statin intolerance: new data and further options for treatment","volume":"36","author":"Diaconu","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib121","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.athplu.2024.01.004_bib122","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.athplu.2024.01.004_bib124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-016-0256-1","article-title":"The genetics and screening of familial hypercholesterolaemia","volume":"23","author":"Henderson","year":"2016","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.athplu.2024.01.004_bib125","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib126","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"12","author":"Watts","year":"2011","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.athplu.2024.01.004_bib127","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2024.01.004_bib128","unstructured":"FDA Evkeeza approval, https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0. Accessed on 20-October-2022 [n.d]."},{"key":"10.1016\/j.athplu.2024.01.004_bib129","unstructured":"EMA Evkeeza authorization. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evkeeza. Accessed on 2-October-2022 n.d. ."},{"key":"10.1016\/j.athplu.2024.01.004_bib130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2022.2090242","article-title":"Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia","volume":"22","author":"Pirillo","year":"2022","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.athplu.2024.01.004_bib131","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib132","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0009-3084(85)90068-4","article-title":"Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes","volume":"38","author":"Wettereau","year":"1985","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.athplu.2024.01.004_bib133","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1074\/jbc.270.12.6549","article-title":"Microsomal triglyceride transfer protein","volume":"270","author":"Jamil","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.athplu.2024.01.004_bib134","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2012.15","article-title":"The genetics of familial combined hyperlipidaemia","volume":"8","author":"Brouwers","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.athplu.2024.01.004_bib135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOL.0000000000000270","article-title":"Combined hyperlipidemia: familial but not (usually) monogenic","volume":"27","author":"Brahm","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib136","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrendo.2016.69","article-title":"Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism","volume":"12","author":"Ellis","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.athplu.2024.01.004_bib137","first-page":"224","article-title":"Familial combined hyperlipidemia: current knowledge, perspectives, and controversies","volume":"70","author":"Bello-Chavolla","year":"2018","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.athplu.2024.01.004_bib138","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2024.01.004_bib139","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacl.2007.07.006","article-title":"Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B","volume":"1","author":"Sniderman","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/geno.1996.0162","article-title":"Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity","volume":"33","author":"Aslanidis","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.athplu.2024.01.004_bib141","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0022-2275(20)32518-9","article-title":"New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease","volume":"39","author":"Pagani","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athplu.2024.01.004_bib142","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","article-title":"Lysosomal acid lipase deficiency \u2013 an under-recognized cause of dyslipidaemia and liver dysfunction","volume":"235","author":"Reiner","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2024.01.004_bib143","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1358\/dot.2016.52.5.2488974","article-title":"Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency","volume":"52","author":"Paton","year":"2016","journal-title":"Drugs Today"},{"key":"10.1016\/j.athplu.2024.01.004_bib144","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11883-023-01092-4","article-title":"Update on sitosterolemia and atherosclerosis","volume":"25","author":"Rocha","year":"2023","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib145","doi-asserted-by":"crossref","first-page":"791","DOI":"10.5551\/jat.RV17052","article-title":"Diagnosis and management of sitosterolemia 2021","volume":"28","author":"Tada","year":"2021","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.athplu.2024.01.004_bib146","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000116766.31036.03","article-title":"Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia","volume":"109","author":"Salen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2024.01.004_bib147","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia--current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.athplu.2024.01.004_bib148","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib149","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.athplu.2024.01.004_bib150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.athplu.2024.01.004_bib151","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1499-3872(14)60033-3","article-title":"Familial chylomicronemia syndrome related chronic pancreatitis: a single-center study","volume":"13","author":"Sisman","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.athplu.2024.01.004_bib152","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score.\u201d","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2024.01.004_bib153","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2174\/1570161116666180209112351","article-title":"Novel hypolipidaemic drugs: mechanisms of action and main metabolic effects","volume":"17","author":"Filippatos","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.athplu.2024.01.004_bib154","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in drug treatment of severe hypertriglyceridemia","volume":"25","author":"Gouni-Berthold","year":"2023","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib156","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2024.01.004_bib157","doi-asserted-by":"crossref","first-page":"802","DOI":"10.5551\/jat.RV17053","article-title":"Current diagnosis and management of tangier disease","volume":"28","author":"Koseki","year":"2021","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.athplu.2024.01.004_bib158","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20945\/2359-3997000000585","article-title":"Very low HDL levels: clinical assessment and management","volume":"67","author":"Bonilha","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.athplu.2024.01.004_bib159","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MOL.0000000000000864","article-title":"Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges","volume":"34","author":"Vitali","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.athplu.2024.01.004_bib160","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2024.01.004_bib161","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"Journal of the American College of Cardiology 2022"},{"key":"10.1016\/j.athplu.2024.01.004_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"The Lancet Regional Health - Europe"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266708952400004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266708952400004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:46:15Z","timestamp":1763023575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266708952400004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":162,"alternative-id":["S266708952400004X"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2024.01.004","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}